Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney DawsonDivision of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Mowbray, Cape Town, South AfricaAndreas H. DiaconDivision of Physiology, Department of Medical Biochemistry, Stellenbosch University, Tygerberg, South Africa; TASK Applied Science, Bellville, South AfricaDaniel E. EverittGlobal Alliance for TB Drug Development, New York, NY, USA. Electronic address: [email protected]Christo van NiekerkPeter R. DonaldDepartment of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South AfricaDivan A. BurgerDepartment of Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa; Quintiles Biostatistics, Bloemfontein, South AfricaRobert SchallDepartment of Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa; Quintiles Biostatistics, Bloemfontein, South AfricaMelvin SpigelmanGlobal Alliance for TB Drug Development, New York, NY, USAAlmari ConradieKathleen D. EisenachDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USAAmour VenterMRC Centre for Tuberculosis Research, Stellenbosch University, Tygerberg, South Africa; Task Applied Science, Tygerberg, South AfricaPrudence IveClinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaLiesl Page‐ShippAurum Institute, Parktown, Johannesburg, South AfricaEbrahim VariavaKlerksdorp Tshepong Hospital Complex, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaKlaus ReitherSwiss Tropical and Public Health Institute, Basel, Switzerland; Ifakara Health Institute, Bagamoyo, TanzaniaNyanda Elias NtinginyaAlexander S. PymFlorian von Groote-BidlingmaierTASK Applied Science, Bellville, South AfricaCarl M. MendelGlobal Alliance for TB Drug Development, New York, NY, USA
2015en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0